Physician profile
Stephen T Drye
NPI 1578786638
$4,994.51
in general payments reported to CMS, 2019-2025
30 companies · $870 in 2025
The $870 reported for 2025 was more than what 95% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $621 · 2021: $519 · 2022: $739 · 2023: $1,014 · 2024: $828 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,712.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $834.44 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $511.28 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $504.12 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $397.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $329.21 | 2020-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $273.06 | 2019-2022 | |
| Abbvie INC. | $271.91 | 2020-2025 | Vraylar |
| Glaxosmithkline, LLC. | $256.76 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $244.75 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $240.32 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.94 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $180.55 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $141.07 | 2019-2022 | |
| Allergan, INC. | $132.63 | 2019 | |
| Dexcom, INC. | $101.98 | 2021-2024 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $53.64 | 2023-2024 | |
| Antares Pharma, INC. | $45.61 | 2020-2025 | Xyosted |
| Abbott Laboratories | $44.53 | 2024-2025 | Proclaim, Freestyle Libre 3 |
| Aytu Biopharma, INC. | $33.63 | 2020-2021 | |
| Acerus Pharmaceuticals Corporation | $28.59 | 2022 | |
| Sanofi Pasteur INC. | $26.97 | 2019-2020 | |
| Genentech USA, INC. | $26.40 | 2019-2021 | |
| Corcept Therapeutics | $25.37 | 2025 | Korlym |
| Vertex Pharmaceuticals Incorporated | $20.39 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.83 | 2022 | |
| Gilead Sciences, INC. | $14.74 | 2020 | |
| Eisai INC. | $14.30 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.06 | 2019 | |
| Dynavax Technologies Corporation | $11.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Drye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.